INO
INOVIO PHARMACEUTICALS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 1 ▼ Inovio Pharmaceuticals is conducting a public offering of common sto…
- Apr 6 ▼ Inovio Pharmaceuticals entered into a material definitive agreement…
- Jul 2 ▼ Inovio Pharmaceuticals (INO) filed a universal shelf registration st…
- Jul 13 ▼ Inovio Pharmaceuticals' universal shelf registration (S-3) filed Jul…
- Jul 30 ▼ Inovio Pharmaceuticals (INO) is raising ~$18.3M net via a 424B5 take…
- Jul 30 ▼ Inovio Pharmaceuticals priced a $20M underwritten public offering of…
- Jul 31 ▼ Inovio Pharmaceuticals priced a $20M public offering of 21M shares a…
- Nov 2 ▲ HC Wainwright & Co. upgrades
- Nov 2 ▲ Inovio Pharmaceuticals announced FDA accelerated approval of VOCERYQ…
- Nov 5 Offering: INOVIO Announces Proposed Public Offering of its Common St…
- Nov 6 ▼ Inovio priced a $75M underwritten public offering of 58.7M shares at…
- Nov 6 Offering: INOVIO Announces Pricing of Approximately $75 Million Publ…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Feb 26. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q3 2026: 23 added (0 new), 2 trimmed or exited.
- AnalystsBULLISH
5 of 7 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +3.7% to 22.10M shares. 1.8 days to cover, ≈20.1% of shares.
- TrendUPTREND
18% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 9.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $20.5M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | $5.6M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | $1.8M |
| Quadrature Capital Ltd | DOUBLED | $1.1M |
| JANE STREET GROUP, LLC | DOUBLED | $894.2K |
| VANGUARD FIDUCIARY TRUST CO | ADD | $759.9K |
| HRT FINANCIAL LP | DOUBLED | $599.0K |
| UBS Group AG | ADD | $467.3K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
7 analystsPrice is below the lowest target. Median implies +329%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 12, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Nov 11, 2026 | Piper Sandler REITERATE | Overweight |
| Nov 6, 2026 | Jefferies MAINTAIN | Buy |
| Nov 2, 2026 | HC Wainwright & Co. UPGRADE | Buy |
| Aug 13, 2026 | Jefferies UPGRADE | Buy |
| Aug 3, 2026 | Piper Sandler REITERATE | Overweight |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Sumner Michael John Chief Medical Officer May 20, 2026 | TAX W/H | $3.3K |
Sumner Michael John Chief Medical Officer May 20, 2026 | EXERCISE | 9,450 sh |
Sumner Michael John Chief Medical Officer May 20, 2026 | AWARD | 46,876 sh |
Sumner Michael John Chief Medical Officer May 20, 2026 | AWARD | 37,684 sh |
Humeau Laurent Chief Scientific Officer May 20, 2026 | EXERCISE | 6,027 sh |
Humeau Laurent Chief Scientific Officer May 20, 2026 | TAX W/H | $2.7K |
Humeau Laurent Chief Scientific Officer May 20, 2026 | AWARD | 34,160 sh |
Humeau Laurent Chief Scientific Officer May 20, 2026 | AWARD | 27,440 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
17 filings · 3 press releases · 1 bullish · 12 bearish · 4 neutral- NEUTRAL SC 13GNov 16, 2026
ADAR1 Capital Management disclosed a 7.4% passive stake in Inovio Pharmaceuticals as of June 30, 2026, consisting of 2,143,910 common shares and 4,285,714 shares underlying warrants. This is a new 5%+ disclosure, adding to a series of passive stake filings by other holders, but the filing…
🔒 Fresh report (last 24h), subscribers only
- BEARISH SC 13G/ANov 16, 2026
Alyeska Investment Group filed an amended Schedule 13G disclosing a 3.32% passive stake in Inovio Pharmaceuticals as of September 30, 2026, down from a prior 5.2% stake (filed August 2026). The reduction below 5% signals a partial exit by a former significant holder.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Highbridge Capital Management filed an amended Schedule 13G disclosing beneficial ownership of 25,288,217 shares of Inovio Pharmaceuticals as of September 30, 2026, representing 9.9% of outstanding common stock (after giving effect to a 9.99% blocker on warrant exercise). This is a passive stake…
🔒 Fresh report (last 24h), subscribers only
- BEARISH 8-KNov 10, 2026
Cash stood at $48.4M pre-offering, with $80.5M in net proceeds from the November 2026 offering…
The earnings release confirms the capital need that drove the $75M dilutive offering 4 days prior. Watch for VOCERYQ launch execution in Q1 2027 and the confirmatory study protocol submission by…
All INO filing & press-release reports (20)
- SC 13G reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 10, 2026
- 8-K reportNov 9, 2026
- 424B5 reportNov 6, 2026
- PRESS-RELEASE reportNov 5, 2026
- 8-K reportNov 5, 2026
- 424B5 reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- SC 13G/A reportNov 5, 2026
- 8-K reportNov 2, 2026
- 8-K reportJul 31, 2026
- 424B5 reportJul 30, 2026
- PRESS-RELEASE reportJul 29, 2026
- EFFECT reportJul 13, 2026
- S-3 reportJul 2, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportApr 6, 2026
- 424B5 reportApr 1, 2026